Ashvattha Therapeutics, a Redwood City, CA-based clinical-stage company advancing a new class of nanomedicine therapeutics, announced additional financing as an extension of its Series B of up to $50M.
The round was led by Tribe Capital and Natural Capital.
The company intends to use the funds to complete the ongoing Phase 2 ophthalmology trial and Phase 1/2 neuroinflammation trial.
Founded by Kannan Rangaramanujam, Sujatha Kannan, and Jeff Cleland, Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells only in regions of inflammation. Its targeted nanomedicine approach seeks to improve precision medicine, empowering a new standard of care across ophthalmology, neurology, and inflammation. Ashvattha’s at-home monthly subcutaneously-administered HDT (hydroxyl dendrimer therapeutic) for neovascular (wet) age-related macular degeneration (wet AMD) and diabetic macula edema (DME) demonstrated substantial reduction in treatment burden. Interim Phase 2 trial results will be presented by Principal Investigator, Dr. Michael Singer, at Angiogenesis 2025 meeting on February 8, 2025.
FinSMEs
14/01/2025